Recruitment

Recruitment Status
Enrolling by invitation
Estimated Enrollment
Same as current

Summary

Conditions
  • Degenerative Disc Disease
  • Degenerative Scoliosis
  • Degenerative Spondylolisthesis
Type
Observational
Design
Observational Model: CohortTime Perspective: Retrospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Patients considered for this study will have previously undergone surgery for their spinal condition according to the standard of care of the practitioner. All patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. Once enrolled in the study,...

Patients considered for this study will have previously undergone surgery for their spinal condition according to the standard of care of the practitioner. All patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. Once enrolled in the study, subjects will undergo a computed tomography (CT) scan at 12 months postoperative or later to evaluate their fusion status. If the patient already had a postoperative CT scan at 12 months or greater, this will be used in this study and an additional CT scan should not be performed for this study. Available progress notes, medical records, patient-reported outcomes, radiographs (plain film and CT scans, if available), and complications will be obtained from the medical records of all enrolled subjects. The safety and performance of the Modulus XLIF interbody implant will be assessed using the following: Complications attributable to the use of the Modulus XLIF interbody implant as noted in surgical summaries, progress notes, and hospital records Radiographic outcome (fusion) and description of device status from plain film radiographs and CT scan(s) Neurologic status, symptoms, and/or subject self-reported clinical outcomes (e.g., pain and disability), as available

Tracking Information

NCT #
NCT04418817
Collaborators
Not Provided
Investigators
Study Director: Kyle Malone, MS NuVasive